Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study-Reference-Cited by-同舟云学术

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study

Published:2017-07 Issue:7 Volume:28 Page:1547-1553
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Voso M.T.,Leone G.,Piciocchi A.,Fianchi L.,Santarone S.,Candoni A.,Criscuolo M.,Masciulli A.,Cerqui E.,Molteni A.,Finelli C.,Parma M.,Poloni A.,Carella A.M.,Spina F.,Cortelezzi A.,Salvi F.,Alessandrino E.P.,Rambaldi A.,Sica S.

Funder

Celgene

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/7/1547/17927438/mdx154.pdf

Reference25 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

2. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

3. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT;Sorror;Blood,2005